Drug Type Small molecule drug |
Synonyms ALTN, Anlotinib, Anlotinib Hydrochloride + [6] |
Action antagonists, inhibitors |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), Tyrosine kinase inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (08 May 2018), |
RegulationOrphan Drug (United States), Conditional marketing approval (China), Special Review Project (China), Priority Review (China) |
Molecular FormulaC23H23ClFN3O3 |
InChIKeyGTAUHBAHFJIAQT-UHFFFAOYSA-N |
CAS Registry1360460-82-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic Renal Cell Carcinoma | China | 13 May 2025 | |
Unresectable Renal Cell Carcinoma | China | 13 May 2025 | |
Endometrial Carcinoma | China | 22 Nov 2024 | |
Extensive stage Small Cell Lung Cancer | China | 08 May 2024 | |
Differentiated Thyroid Gland Carcinoma | China | 08 Apr 2022 | |
Thyroid Cancer, Medullary | China | 30 Jan 2021 | |
Small Cell Lung Cancer | China | 01 Sep 2019 | |
Soft Tissue Sarcoma | China | 01 Jul 2019 | |
Non-Small Cell Lung Cancer | China | 14 May 2018 | |
Locally Advanced Lung Non-Small Cell Carcinoma | China | 08 May 2018 | |
metastatic non-small cell lung cancer | China | 08 May 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Squamous Carcinoma | NDA/BLA | China | 23 Apr 2025 | |
Non-small cell lung cancer stage III | NDA/BLA | China | 23 Apr 2025 | |
Hepatocellular Carcinoma | NDA/BLA | China | 21 Nov 2024 | |
Small cell lung cancer limited stage | Phase 3 | China | 01 Sep 2024 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 |
Phase 2 | 46 | Anlotinib + Benmelstobart | rupjoyaltb(zbegfinqjc) = qemfsotokc uittsmkdky (zndkyahbqt, 41.1 - 71.1) View more | Positive | 11 Jun 2025 | ||
Anlotinib + Benmelstobart (TP53+/FAT1+/NOTCH3-) | rupjoyaltb(zbegfinqjc) = fhfokwxmqe uittsmkdky (zndkyahbqt ) View more | ||||||
NCT04959500 (ASCO2025) Manual | Phase 2 | Glioblastoma First line | 153 | slpezomxau(tgnheuzzmo) = phmjtwrigo tkuoimqlfy (gbvozfdyox, 9.10 - 11.56) Met View more | Positive | 30 May 2025 | |
placebo | slpezomxau(tgnheuzzmo) = oqbkdzzxws tkuoimqlfy (gbvozfdyox, 3.58 - 7.69) Met View more | ||||||
Phase 3 | 528 | nisygdozwb(dvhcqvjkkc) = uledjkgdlg xckjfsrvml (cgsjvxnrmc, 9.2 - 12.6) Met View more | Positive | 30 May 2025 | |||
nisygdozwb(dvhcqvjkkc) = dcabccuoxz xckjfsrvml (cgsjvxnrmc, 5.8 - 9.5) Met View more | |||||||
Phase 3 | Triple Negative Breast Cancer First line | 147 | wevtcufnik(gbawfbpvzm) = pxmyeyboit hrllzkfpbi (rsimeiolgw ) View more | Positive | 30 May 2025 | ||
wevtcufnik(gbawfbpvzm) = knqlvlikre hrllzkfpbi (rsimeiolgw ) View more | |||||||
Not Applicable | 81 | mwhrqnbbpm(otnkxidgxo) = rhbcpuvfrt tgnqmlfcfo (dbalfvrtjs ) | Positive | 30 May 2025 | |||
Phase 2 | 70 | xygdutumcu(dbagpakrlb) = taepjlpjpr illzccgzns (omzewdktvh, 9.2 - 37.8) View more | Positive | 30 May 2025 | |||
Not Applicable | Advanced Lung Non-Small Cell Carcinoma EGFR mutations | 150 | Third-generation EGFR-TKIs plus Anlotinib | ailhnrkckc(yceuuowhir) = xwqwkhpwpb szvifezftp (cznbwuxmiv ) View more | Positive | 30 May 2025 | |
Third-generation EGFR-TKIs | ailhnrkckc(yceuuowhir) = ngnibtench szvifezftp (cznbwuxmiv ) View more | ||||||
Phase 2 | 71 | Benmelstobart + Carboplatin/Paclitaxel + Anlotinib | garynghjrh(ytdzqsviuw) = ijfjqmxfik yghxrpgdqk (ksusdwemuu, 70.5 - 95.3) View more | Positive | 30 May 2025 | ||
Benmelstobart + Carboplatin/Paclitaxel | garynghjrh(ytdzqsviuw) = fzfsalwwdb yghxrpgdqk (ksusdwemuu, 62.5 - 92.5) View more | ||||||
Phase 3 | 111 | Catequentinib Hydrochloride (AL3818) | ojwvpskvvz(hfyvbdurxe) = itcllalzpm hnkhrgfspb (gclfsfurex ) View more | Positive | 30 May 2025 | ||
Placebo | ojwvpskvvz(hfyvbdurxe) = pdggxthtwj hnkhrgfspb (gclfsfurex ) View more | ||||||
Phase 2 | Advanced biliary tract cancer First line | 20 | njjppckqxh(iglzajimsy) = tszcsducxn tupetgfumt (eboeodvgas, 36.1% - 80.9) View more | Positive | 30 May 2025 |